← All trials
NCT05974748
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2023
- Primary completion
- Aug 15, 2023
- Completion date
- Aug 15, 2023
- First posted
- Aug 3, 2023
- Last posted
- Sep 7, 2023
- Enrollment
- 44
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dow University of Health SciencesLead sponsor
- Dow University of Health SciencesReponsible party - principal investigator
- Dow University of Health SciencesSponsor investigator
- Dow University of Health SciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.